Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma [clinicaltrials:NCT00031733]
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma [clinicaltrials:NCT00031733]
Bio2RDF identifier
NCT00031733
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00031733
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Vaccines mad ...... ge III, or stage IV melanoma.
brief title [clinicaltrials_vocabulary:brief-title]
Vaccine Therapy and Interleuki ...... reating Patients With Melanoma
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2007-11-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... s
study within 3 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2002-03-08T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
is section 801 [clinicaltrials_vocabulary:is-section-801]
keyword [clinicaltrials_vocabulary:keyword]
ciliary body and choroid melanoma, medium/large size
ciliary body and choroid melanoma, small size
extraocular extension melanoma
iris melanoma
recurrent intraocular melanoma
recurrent melanoma
stage II melanoma
stage III melanoma
stage IV melanoma
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2014-05-20T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00031733
official title [clinicaltrials_vocabulary:official-title]
A Phase II Randomized Trial of ...... ges IIB/C, III and IV Melanoma
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000069220 (10M-01-1)
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2004-12-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
LAC-USC-10M011
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2002-02-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2014-05-01T00:00:00Z
identifier
clinicaltrials:NCT00031733
title
Vaccine Therapy and Interleuki ...... reating Patients With Melanoma
@en
type
label
Vaccine Therapy and Interleuki ...... a [clinicaltrials:NCT00031733]
@en